TherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.
Industry, Sector and Symbol:
Capitalization:- Market Cap: $1.1 billion
- Outstanding Shares: 203,927,000
Average Prices:- 50 Day Moving Avg: $5.04
- 200 Day Moving Avg: $5.56
- 52 Week Range: $3.50 - $8.30
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -53.70
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $18.41 million
- Price / Sales: 59.48
- Book Value: $0.56 per share
- Price / Book: 9.59
Profitability:- EBIDTA: ($90,400,000.00)
- Net Margins: -530.84%
- Return on Equity: -71.36%
- Return on Assets: -63.59%
Misc:- Average Volume: 2.84 million shs.
- Short Ratio: 19.16
Frequently Asked Questions for TherapeuticsMD (NASDAQ:TXMD)
What is TherapeuticsMD's stock symbol?
TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."
When will TherapeuticsMD make its next earnings announcement?
Where is TherapeuticsMD's stock going? Where will TherapeuticsMD's stock price be in 2017?
7 analysts have issued 12-month price objectives for TherapeuticsMD's stock. Their forecasts range from $10.00 to $33.00. On average, they anticipate TherapeuticsMD's stock price to reach $16.14 in the next year. View Analyst Ratings for TherapeuticsMD.
Who are some of TherapeuticsMD's key competitors?
Some companies that are related to TherapeuticsMD include Supernus Pharmaceuticals (SUPN), Advanced Accelerator Applications S.A. (AAAP), Repligen Corporation (RGEN), Eagle Pharmaceuticals (EGRX), Aimmune Therapeutics (AIMT), Assembly Biosciences (ASMB), Rockwell Medical (RMTI), Novan (NOVN), Check-Cap (CHEK), CorMedix (CRMD), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).
Who are TherapeuticsMD's key executives?
TherapeuticsMD's management team includes the folowing people:
- Tommy G. Thompson J.D., Independent Chairman of the Board
- John C. K. Milligan IV, President, Secretary, Director
- Robert G. Finizio, Chief Executive Officer, Director
- Daniel A. Cartwright, Chief Financial Officer, Treasurer
- Mitchell L. Krassan, Executive Vice President, Chief Strategy Officer
- Michael Donegan, Vice President - Finance
- Brian Bernick M.D., Chief Clinical Officer, Director
- Jules A. Musing, Director
- J. Martin Carroll, Independent Director
- Cooper C. Collins, Independent Director
Who owns TherapeuticsMD stock?
TherapeuticsMD's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Sanders Morris Harris LLC (0.28%), Capital Impact Advisors LLC (0.06%), Bank of Montreal Can (0.04%) and Aperio Group LLC (0.02%). View Institutional Ownership Trends for TherapeuticsMD.
Who sold TherapeuticsMD stock? Who is selling TherapeuticsMD stock?
Who bought TherapeuticsMD stock? Who is buying TherapeuticsMD stock?
How do I buy TherapeuticsMD stock?
Shares of TherapeuticsMD can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TherapeuticsMD's stock price today?
One share of TherapeuticsMD stock can currently be purchased for approximately $5.37.
MarketBeat Community Rating for TherapeuticsMD (NASDAQ TXMD)MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for TherapeuticsMD (NASDAQ:TXMD) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 7 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $16.14 (200.61% upside) |
Analysts' Ratings History for TherapeuticsMD (NASDAQ:TXMD)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/21/2017 | Cantor Fitzgerald | Reiterated Rating | Overweight | $33.00 | Low |  |
| 7/21/2017 | Deutsche Bank AG | Initiated Coverage | Buy | $10.00 | Medium | |
| 7/17/2017 | Cowen and Company | Reiterated Rating | Outperform | $13.00 | Low | |
| 7/11/2017 | CIBC | Upgrade | Market Perform -> Outperform | | High | |
| 7/11/2017 | Oppenheimer Holdings, Inc. | Upgrade | Market Perform -> Outperform | $10.00 | High | |
| 6/14/2017 | Jefferies Group LLC | Set Price Target | Buy | $15.00 | High | |
| 5/24/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $20.00 | High | |
(Data available from 7/21/2015 forward)
Earnings History for TherapeuticsMD (NASDAQ:TXMD)Earnings History by Quarter for TherapeuticsMD (NASDAQ TXMD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/2/2017 | | ($0.11) | | | | | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for TherapeuticsMD (NASDAQ:TXMD)Current Year EPS Consensus Estimate: $-0.45 EPS
Next Year EPS Consensus Estimate: $-0.10 EPS
Dividend History for TherapeuticsMD (NASDAQ:TXMD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for TherapeuticsMD (NASDAQ:TXMD)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for TherapeuticsMD (NASDAQ:TXMD)
Latest Headlines for TherapeuticsMD (NASDAQ:TXMD)
| Source: |
|
| Date | Headline |
|---|
 | Cowen and Company Reiterates Outperform Rating for TherapeuticsMD Inc (TXMD)
www.americanbankingnews.com - July 17 at 10:20 PM |
 | Why TherapeuticsMD Inc Is Getting Clobbered
www.fool.com - July 17 at 12:46 PM |
| CIBC Upgrades TherapeuticsMD Inc (TXMD) to Outperform
www.americanbankingnews.com - July 11 at 2:58 PM |
| TherapeuticsMD Inc (TXMD) Lifted to Outperform at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - July 11 at 10:43 AM |
| TherapeuticsMD Inc (NASDAQ:TXMD) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 11 at 10:06 AM |
| TherapeuticsMD Target of Unusually Large Options Trading (TXMD)
www.americanbankingnews.com - July 9 at 7:08 AM |
 | Profit From TherapeuticsMD's Upcoming FDA Catalyst
seekingalpha.com - July 6 at 2:53 PM |
| $4.95 Million in Sales Expected for TherapeuticsMD Inc (TXMD) This Quarter
www.americanbankingnews.com - July 1 at 9:54 AM |
| Analysts Anticipate TherapeuticsMD Inc (TXMD) Will Announce Earnings of -$0.10 Per Share
www.americanbankingnews.com - June 29 at 7:48 AM |
| TherapeuticsMD (TXMD) & Check-Cap (CHEK) Financial Analysis
www.americanbankingnews.com - June 18 at 6:02 PM |
| TherapeuticsMD Inc (TXMD) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 15 at 4:36 PM |
 | EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of a Class Action to Recover Losses Suffered by Investors in TherapeuticsMD, Inc.
finance.yahoo.com - June 15 at 3:41 PM |
| MONDAY DEADLINE: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 15 at 3:41 PM |
| Analysts Anticipate TherapeuticsMD Inc (TXMD) to Post ($0.10) EPS
www.americanbankingnews.com - June 15 at 2:52 PM |
| TherapeuticsMD Inc (TXMD) Given a $15.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - June 15 at 2:32 PM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of a Class Action to Recover Losses Suffered by Investors in TherapeuticsMD, Inc. and a Lead Plaintiff Deadline of June 19, 2017 - TXMD
finance.yahoo.com - June 8 at 1:34 AM |
| DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against TherapeuticsMD, Inc. (TXMD) and Lead Plaintiff Deadline - June 19, 2017
finance.yahoo.com - June 8 at 1:34 AM |
| APPROACHING DEADLINE: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 8 at 1:34 AM |
| TherapeuticsMD Inc (TXMD) Expected to Announce Quarterly Sales of $4.95 Million
www.americanbankingnews.com - June 7 at 1:06 PM |
| Analysts Expect TherapeuticsMD Inc (TXMD) Will Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - June 5 at 8:04 AM |
| Zacks: TherapeuticsMD Inc (TXMD) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - May 26 at 2:32 PM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against TherapeuticsMD, Inc. (TXMD) and Lead Plaintiff Deadline: June 19, 2017
finance.yahoo.com - May 25 at 5:54 AM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of a Complaint to Recover Losses Suffered by Investors in TherapeuticsMD, Inc. - Sets Lead Plaintiff Deadline of June 19, 2017 - TXMD
finance.yahoo.com - May 25 at 5:54 AM |
| IMPORTANT THERAPEUTICSMD, INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of Florida against TherapeuticsMD, Inc.
finance.yahoo.com - May 25 at 5:54 AM |
| TherapeuticsMD's (TXMD) Buy Rating Reaffirmed at Stifel Nicolaus
www.americanbankingnews.com - May 24 at 10:18 PM |
| TherapeuticsMD Inc (TXMD) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - May 12 at 11:56 PM |
| TherapeuticsMD Inc (TXMD) Expected to Post Quarterly Sales of $4.95 Million
www.americanbankingnews.com - May 11 at 11:00 AM |
 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TherapeuticsMD, Inc. - TXMD
www.bizjournals.com - May 11 at 2:32 AM |
| INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 11 at 2:32 AM |
| TherapeuticsMD Announces Presentation at Bank of America Merrill Lynch 2017 Healthcare Conference on May 16
finance.yahoo.com - May 11 at 2:32 AM |
| Cantor Fitzgerald Reaffirms "Overweight" Rating for TherapeuticsMD Inc (TXMD)
www.americanbankingnews.com - May 10 at 9:58 AM |
| Zacks: TherapeuticsMD Inc (TXMD) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - May 9 at 6:38 PM |
| -$0.10 Earnings Per Share Expected for TherapeuticsMD Inc (TXMD) This Quarter
www.americanbankingnews.com - May 9 at 4:32 PM |
| TherapeuticsMD Inc (TXMD) Lowered to Market Perform at Oppenheimer Holdings Inc.
www.americanbankingnews.com - May 9 at 10:26 AM |
| Oppenheimer Holdings Inc. Reiterates Market Perform Rating for TherapeuticsMD Inc (TXMD)
www.americanbankingnews.com - May 9 at 8:36 AM |
 | FDA rejects TherapeuticsMD's vaginal pain drug
www.nasdaq.com - May 8 at 9:33 AM |
| TherapeuticsMD Receives Complete Response Letter from FDA for TX-004HR New Drug Application
finance.yahoo.com - May 8 at 9:33 AM |
| FDA rejects TherapeuticsMD's vaginal pain drug; shares slump
finance.yahoo.com - May 8 at 9:33 AM |
| TherapeuticsMD Rejected by FDA, Delay Could be Fatal
finance.yahoo.com - May 8 at 9:33 AM |
| IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 6 at 9:08 AM |
| SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against TherapeuticsMD, Inc. (TXMD) and Lead Plaintiff Deadline: June 19, 2017
finance.yahoo.com - May 3 at 6:40 PM |
| IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 3 at 6:40 PM |
| The Klein Law Firm Announces the Commencement of a Class Action Filed on Behalf of TherapeuticsMD, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2017
finance.yahoo.com - May 3 at 6:40 PM |
| INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 3 at 6:40 PM |
| TherapeuticsMD Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 2 at 6:25 PM |
| TherapeuticsMD to Host TX-004HR Regulatory Update Conference Call and Webcast on May 8
finance.yahoo.com - May 2 at 6:25 PM |
| IMPORTANT EQUITY ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 2 at 6:25 PM |
| TherapeuticsMD (TXMD) Given Daily Media Sentiment Rating of 0.22
www.americanbankingnews.com - May 2 at 4:46 PM |
| TherapeuticsMD (TXMD) Receives Coverage Optimism Score of 0.15
www.americanbankingnews.com - April 28 at 2:36 PM |
| The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of TherapeuticsMD, Inc. Investors and Encourages Investors to Contact the Firm
finance.yahoo.com - April 26 at 4:53 PM |
TherapeuticsMD (TXMD) Chart for Friday, July, 21, 2017
